BioNTech's US stock fell about 10% before the market, and the company announced the termination of phase II clinical trials for colorectal cancer.

Zhitongcaijing · 1d ago
BioNTech's US stock fell about 10% before the market, and the company announced the termination of phase II clinical trials for colorectal cancer.